MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

---

Intestinal Barrier and Permeability in Health, Obesity and NAFLD

Biomedicines, Journal Year: 2021, Volume and Issue: 10(1), P. 83 - 83

Published: Dec. 31, 2021

The largest surface of the human body exposed to external environment is gut. At this level, intestinal barrier includes luminal microbes, mucin layer, gastrointestinal motility and secretion, enterocytes, immune cells, gut vascular barrier, liver barrier. A healthy characterized by selective permeability nutrients, metabolites, water, bacterial products, processes are governed cellular, neural, immune, hormonal factors. Disrupted (leaky syndrome) can represent a predisposing or aggravating condition in obesity metabolically associated steatosis (nonalcoholic fatty disease, NAFLD). In what follows, we describe morphological-functional features role major modifiers discuss recent evidence pointing key obesity/NAFLD.

Language: Английский

---

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 6, 2024

Abstract Background Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated (MAFLD) shares common pathophysiological mechanisms with type 2 diabetes, making them significant risk factors for diabetes. The present study aimed to assess the epidemiological feature of diabetes in patients NAFLD or MAFLD at global levels. Methods Published studies were searched terms that included using PubMed, EMBASE, MEDLINE, Web Science databases from their inception December 2022. pooled regional prevalence incidence density evaluated random-effects meta-analysis. Potential sources heterogeneity investigated stratified meta-analysis meta-regression. Results A total 395 (6,878,568 participants NAFLD; 1,172,637 MAFLD) 40 countries areas among was 28.3% (95% confidence interval 25.2–31.6%) 26.2% (23.9–28.6%) globally. 24.6 per 1000-person year (20.7 29.2) 26.9 (7.3 44.4), respectively. Conclusions describes MAFLD. findings serve as a valuable resource clinical economic impact

Language: Английский

---

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)

Journal of Clinical and Translational Hepatology, Journal Year: 2024, Volume and Issue: 000(000), P. 000 - 000

Published: Nov. 4, 2024

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, dysfunction-associated non-alcoholic fatty liver disease has become most prevalent chronic disease. This condition frequently occurs Chinese patients with alcoholic hepatitis B. To address impending public health crisis its underlying issues, Society Hepatology Medical Association convened a panel clinical experts to revise update "Guideline prevention treatment (2018, China)". The new edition, titled for (Version 2024)", offers comprehensive recommendations on key including screening monitoring, diagnosis evaluation, treatment, follow-up steatotic Metabolic is now preferred English term used interchangeably Additionally, guideline emphasizes importance multidisciplinary collaboration among hepatologists other specialists manage cardiometabolic disorders effectively.

Language: Английский

---

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Clinical and Molecular Hepatology, Journal Year: 2021, Volume and Issue: 28(2), P. 150 - 163

Published: Nov. 10, 2021

Fatty liver is now a major cause of disease in the Asia-Pacific region. Liver diseases this region have distinctive characteristics. First, fatty frequently observed lean/normal-weight individuals. However, there no standard definition unique phenotype. Second, often patients with concomitant viral hepatitis. The exclusion hepatitis from non-alcoholic limits its value and detracts investigation holistic management coexisting Third, liver-associated hepatocellular carcinoma (HCC) generally categorized as non-B non-C HCC. Fourth, population aging rapidly, it imperative to develop practicable, low-intensity exercise program for elderly patients. Fifth, most nonspecialized healthcare professionals still lack an awareness significance both terms intrahepatic extrahepatic cancer. Recently, international expert panel proposed new liver: metabolic dysfunction-associated (MAFLD). One feature MAFLD that dysfunction prerequisite diagnosis. Pertinent regional issues, also provides diagnostic criteria Furthermore, independent any disease, including Therefore, may be more suitable In review, we introduce characteristics discuss advantages improving clinical practice

Language: Английский

---

Metabolic dysfunction-associated fatty liver disease: a year in review

Current Opinion in Gastroenterology, Journal Year: 2022, Volume and Issue: 38(3), P. 251 - 260

Published: Feb. 9, 2022

Purpose of review In 2020, a novel comprehensive redefinition fatty liver disease was proposed by an international panel experts. This aims to explore current evidence regarding the impact this new definition on understanding epidemiology, pathogenesis, diagnosis, and clinical trials for disease. Recent findings The effectiveness metabolic dysfunction-associated (MAFLD) compared existing criteria nonalcoholic (NAFLD). data robustly suggest superior utility MAFLD in identifying patients at high risk dysfunction, hepatic extra-hepatic complications, as well those who would benefit from genetic testing, including with concomitant diseases. change name also appears have improved awareness among physicians. Summary transformation NAFLD represents important milestone, which indicates significant tangible progress towards more inclusive, equitable, patient-centred approach addressing profound challenges Growing has illustrated broader specific contexts that tremendous potential positively influencing diagnosis treatment. addition, momentum accompanying included widespread public attention unique burden previously underappreciated

Language: Английский

---

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 28(4), P. 790 - 801

Published: May 11, 2022

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population and is major public health concern. NAFLD defined by presence hepatic steatosis absence other causes disease. As closely associated with metabolic syndrome, several experts have called for change in nomenclature from to metabolic-associated (MAFLD) better reflect underlying pathophysiology as metabolically driven shift "positive" diagnostic criteria rather than one exclusion. Recent studies suggested that global prevalence MAFLD higher NAFLD, patients more comorbidities compared those NAFLD. Emerging data also suggest all-cause cardiovascular mortality may be In this synopsis, we discuss differences clinical features, outcomes between MAFLD. addition, highlight advantages disadvantages name perspective scientific community, care providers patients.

Language: Английский

---

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

Endocrine Practice, Journal Year: 2022, Volume and Issue: 28(7), P. 667 - 672

Published: March 30, 2022

Language: Английский

---

Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction–associated Fatty Liver Disease

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 107(8), P. e3295 - e3303

Published: May 6, 2022

Abstract Context Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between and metabolic dysfunction–associated fatty liver disease (MAFLD) remains unclear. Objective This study aimed to explore with MAFLD its long-term mortality. Methods We extracted data from NHANES III, 1988 to1994 linked mortality until December 31, 2015. The was analyzed by multivariable logistic regression. Cox proportional hazards regression performed assess whether elevated increased all-cause cause-specific mortalities in patients. Results At baseline, 28.6% (1474/5156) participants had MAFLD. In regression, fourth quartile associated an risk compared first (odds ratio [OR]: 1.714; 95% CI, 1.586-1.971; P < .001). normal levels triglycerides, low-density lipoprotein high-density cholesterol, relationship remained significant (OR: 1.346; 1.248-1.761; During a median follow-up 307 months, patients were higher (hazard [HR]: 2.183; 1.825-2.407; .001), as well (HR: 2.346; 2.046-2.885; .001) cancer-related 2.366; 1.864-2.932; quartile. Conclusion Remnant predicted all-cause, cardiovascular,

Language: Английский

---

Steatotic liver disease, MASLD and risk of chronic kidney disease

Diabetes & Metabolism, Journal Year: 2023, Volume and Issue: 50(1), P. 101506 - 101506

Published: Dec. 21, 2023

With the rising tide of fatty liver disease related to metabolic dysfunction worldwide, association this common with chronic kidney (CKD) has become increasingly evident. In 2020, more inclusive term dysfunction-associated (MAFLD) was proposed replace old nonalcoholic (NAFLD). 2023, a modified Delphi process led by three large pan-national associations. There consensus change nomenclature and definition include presence at least one five cardiometabolic risk factors as diagnostic criteria. The name chosen NAFLD steatotic (MASLD). from MAFLD then MASLD resulted in reappraisal epidemiological trends associations developing CKD. observed between MAFLD/MASLD CKD our understanding that can be an epiphenomenon linked underlying support notion individuals are substantially higher incident than those without MASLD. This narrative review provides overview literature on (a) evolution criteria for diagnosing highly prevalent disease, (b) evidence linking CKD, (c) mechanisms which (and strongly MASLD) may increase (d) potential drug treatments benefit both

Language: Английский

---